Juvenile idiopathic arthritis: State of the art and future perspectives

Alberto Martini, Daniel J. Lovell

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Juvenile idiopathic arthritis (JIA) is not a disease but an exclusion diagnosis that includes all forms of chronic arthritis of unknown origin with onset before 16 years of age. The current classification identifies several different categories. While some of them appear to represent rather homogeneous entities others seem still to include heterogeneous conditions. The advent of the new biological treatments has dramatically changed both the observed responses to treatment and the expectations of treatments. International research networks of paediatric rheumatology have contributed to fostering the conduct of controlled clinical trials and also the development of validated outcome measures. However, despite a dramatic advance in the understanding of JIA categories, pathobiology and treatments, much remains to be done.

Original languageEnglish
Pages (from-to)1260-1263
Number of pages4
JournalAnnals of the Rheumatic Diseases
Volume69
Issue number7
DOIs
Publication statusPublished - Jul 2010

Fingerprint

Pediatrics
Juvenile Arthritis
Foster Home Care
Controlled Clinical Trials
Rheumatology
Therapeutics
Arthritis
Outcome Assessment (Health Care)
Research

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology
  • Immunology and Allergy
  • Rheumatology

Cite this

Juvenile idiopathic arthritis : State of the art and future perspectives. / Martini, Alberto; Lovell, Daniel J.

In: Annals of the Rheumatic Diseases, Vol. 69, No. 7, 07.2010, p. 1260-1263.

Research output: Contribution to journalArticle

@article{f48c7c86039e498fae2f8fc9e8bff612,
title = "Juvenile idiopathic arthritis: State of the art and future perspectives",
abstract = "Juvenile idiopathic arthritis (JIA) is not a disease but an exclusion diagnosis that includes all forms of chronic arthritis of unknown origin with onset before 16 years of age. The current classification identifies several different categories. While some of them appear to represent rather homogeneous entities others seem still to include heterogeneous conditions. The advent of the new biological treatments has dramatically changed both the observed responses to treatment and the expectations of treatments. International research networks of paediatric rheumatology have contributed to fostering the conduct of controlled clinical trials and also the development of validated outcome measures. However, despite a dramatic advance in the understanding of JIA categories, pathobiology and treatments, much remains to be done.",
author = "Alberto Martini and Lovell, {Daniel J.}",
year = "2010",
month = "7",
doi = "10.1136/ard.2010.133033",
language = "English",
volume = "69",
pages = "1260--1263",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "7",

}

TY - JOUR

T1 - Juvenile idiopathic arthritis

T2 - State of the art and future perspectives

AU - Martini, Alberto

AU - Lovell, Daniel J.

PY - 2010/7

Y1 - 2010/7

N2 - Juvenile idiopathic arthritis (JIA) is not a disease but an exclusion diagnosis that includes all forms of chronic arthritis of unknown origin with onset before 16 years of age. The current classification identifies several different categories. While some of them appear to represent rather homogeneous entities others seem still to include heterogeneous conditions. The advent of the new biological treatments has dramatically changed both the observed responses to treatment and the expectations of treatments. International research networks of paediatric rheumatology have contributed to fostering the conduct of controlled clinical trials and also the development of validated outcome measures. However, despite a dramatic advance in the understanding of JIA categories, pathobiology and treatments, much remains to be done.

AB - Juvenile idiopathic arthritis (JIA) is not a disease but an exclusion diagnosis that includes all forms of chronic arthritis of unknown origin with onset before 16 years of age. The current classification identifies several different categories. While some of them appear to represent rather homogeneous entities others seem still to include heterogeneous conditions. The advent of the new biological treatments has dramatically changed both the observed responses to treatment and the expectations of treatments. International research networks of paediatric rheumatology have contributed to fostering the conduct of controlled clinical trials and also the development of validated outcome measures. However, despite a dramatic advance in the understanding of JIA categories, pathobiology and treatments, much remains to be done.

UR - http://www.scopus.com/inward/record.url?scp=77954976614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954976614&partnerID=8YFLogxK

U2 - 10.1136/ard.2010.133033

DO - 10.1136/ard.2010.133033

M3 - Article

C2 - 20525835

AN - SCOPUS:77954976614

VL - 69

SP - 1260

EP - 1263

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 7

ER -